Phase 1b Study Evaluating Safety and Feasibility of Exercise and Spermidine Combined With Lamivudine or Rapamycin to Reduce Inflammation and Aging in Adults 65 to 80 Years

What this Trial Is About

Researchers are evaluating the feasibility of an anti-aging intervention combining an exercise regimen, spermidine supplementation, and either lamivudine or rapamycin in adults aged 65 to 80 years who are current or former smokers. This Phase 1b clinical trial aims to assess safety and the impact of these interventions on systemic inflammation and aging-related changes. Participants will be randomly assigned to one of two groups one group will perform an exercise regimen and take spermidine along with lamivudine for 180 days, while the other group will perform the same exercise regimen and take spermidine with rapamycin for 180 days. The exercise program includes high-intensity interval training twice a week and resistance training three times a week. Spermidine is given orally at 2 mg per day. During the study, researchers will monitor participants for adverse events and their ability to complete more than 80% of the pharmacological intervention. They will also measure inflammation markers like the neutrophil to lymphocyte ratio at 180 days. Safety and feasibility will be closely observed, with the total participation lasting about six months.

A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation